Genetic variants of human granzyme B predict transplant outcomes after HLA matched unrelated bone marrow transplantation for myeloid malignancies

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Espinoza, Luis J ^a   Takami, Akiyoshi ^a   Nakata, Katsuya ^a   Yamada, Kayoko ^a   Onizuka, Makoto ^b   Kawase, Takakazu ^c   Sao, Hiroshi ^d   Akiyama, Hideki ^e   Miyamura, Koichi ^f   Okamoto, Shinichiro ^g   Inoue, Masami ^h   Fukuda, Takahiro ⁱ   Morishima, Yasuo ^c   Kodera, Yoshihisa ^j   Nakao, Shinji ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d Meitetsu Hospital   (Japan)

^e Department of Dentistry Oral surgery   (Japan)

^f JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^g KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

ⁱ NATIONAL CANCER CENTER HOSPITAL   (Japan)

^j AICHI MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GRANZYME B; GRANZYME; HLA ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DONOR; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GRAFT RECIPIENT; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PROGNOSIS; TREATMENT OUTCOME; ALLOTRANSPLANTATION; BLOOD DISEASE; BONE MARROW TRANSPLANTATION; GENETICS; GENOTYPE; IMMUNOLOGY; INFANT; MIDDLE AGED; MORTALITY; MYELOPROLIFERATIVE DISORDER; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGED; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; GENETIC VARIATION; GENOTYPE; GRANZYMES; HEMATOLOGIC NEOPLASMS; HLA ANTIGENS; HUMANS; INFANT; MIDDLE AGED; MORTALITY; MYELOPROLIFERATIVE DISORDERS; POLYMORPHISM, GENETIC; PROGNOSIS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051956736     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023827     Document Type: Article

References (53)

1. Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, et al. (2005) Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 36: 757-769.
2. Dickinson AM, Middleton PG, Rocha V, Gluckman E, Holler E, (2004) Genetic polymorphisms predicting the outcome of bone marrow transplants. Br J Haematol 127: 479-490.
3. de Boer MGJ, Jolink H, Halkes CJM, van der Heiden PLJ, Kremer D, et al. (2011) Influence of Polymorphisms in Innate Immunity Genes on Susceptibility to Invasive Aspergillosis after Stem Cell Transplantation. PLoS One 6: e18403.
4. Elmaagacli AH, Koldehoff M, Landt O, Beelen DW, (2008) Relation of an interleukin-23 receptor gene polymorphism to graft-versus-host disease after hematopoietic-cell transplantation. Bone Marrow Transplant 41: 821-826.
5. Gerbitz A, Hillemanns P, Schmid C, Wilke A, Jayaraman R, et al. (2008) Influence of polymorphism within the heme oxygenase-I promoter on overall survival and transplantation-related mortality after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 14: 1180-1189.
6. Kim DH, Jung HD, Lee NY, Sohn SK, (2007) Single nucleotide polymorphism of CC chemokine ligand 5 promoter gene in recipients may predict the risk of chronic graft-versus-host disease and its severity after allogeneic transplantation. Transplantation 84: 917-925.
7. Noori-Daloii MR, Rashidi-Nezhad A, Izadi P, Hossein-Nezhad A, Sobhani M, et al. (2007) Transforming growth factor-beta1 codon 10 polymorphism is associated with acute GVHD after allogenic BMT in Iranian population. Ann Transplant 12: 5-10.
8. Viel DO, Tsuneto LT, Sossai CR, Lieber SR, Marques SB, et al. (2007) IL2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Scand J Immunol 66: 703-710.
9. Sugimoto K, Murata M, Onizuka M, Inamoto Y, Terakura S, et al. (2008) Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype. Int J Hematol 87: 451-458.
10. Ostrovsky O, Shimoni A, Rand A, Vlodavsky I, Nagler A, (2010) Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors. Blood 115: 2319-2328.
11. Takami A, Espinoza JL, Onizuka M, Ishiyama K, Kawase T, et al. (2010) A single-nucleotide polymorphism of the Fcgamma receptor type IIIA gene in the recipient predicts transplant outcomes after HLA fully matched unrelated BMT for myeloid malignancies. Bone Marrow Transplant.
12. McDermott DH, Conway SE, Wang T, Ricklefs SM, Agovi MA, et al. (2010) Donor and recipient chemokine receptor CCR5 genotype is associated with survival after bone marrow transplantation. Blood 115: 2311-2318.
13. Espinoza JL, Takami A, Onizuka M, Sao H, Akiyama H, et al. (2009) NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies. Haematologica 94: 1427-1434.
14. Espinoza JL, Takami A, Onizuka M, Kawase T, Sao H, et al. (2011) A single nucleotide polymorphism of IL-17 gene in the recipient is associated with acute GVHD after HLA-matched unrelated BMT. Bone Marrow Transplant.
15. Chowdhury D, Lieberman J, (2008) Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol 26: 389-420.
16. Krupnick AS, Kreisel D, Popma SH, Balsara KR, Szeto WY, et al. (2002) Mechanism of T cell-mediated endothelial apoptosis. Transplantation 74: 871-876.
17. Graubert TA, DiPersio JF, Russell JH, Ley TJ, (1997) Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 100: 904-911.
18. Boivin WA, Cooper DM, Hiebert PR, Granville DJ, (2009) Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab Invest 89: 1195-1220.
19. Jahrsdörfer B, Vollmer A, Blackwell SE, Maier J, Sontheimer K, et al. (2010) Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood 115: 1156-1165.
20. Prakash MD, Bird CH, Bird PI, (2009) Active and zymogen forms of granzyme B are constitutively released from cytotoxic lymphocytes in the absence of target cell engagement. Immunol Cell Biol 87: 249-254.
21. Strik MC, de Koning PJ, Kleijmeer MJ, Bladergroen BA, Wolbink AM, et al. (2007) Human mast cells produce and release the cytotoxic lymphocyte associated protease granzyme B upon activation. Mol Immunol 44: 3462-3472.
22. Wagner C, Iking-Konert C, Denefleh B, Stegmaier S, Hug F, et al. (2004) Granzyme B and perforin: constitutive expression in human polymorphonuclear neutrophils. Blood 103: 1099-1104.
23. Lauw FN, Simpson AJ, Hack CE, Prins JM, Wolbink AM, et al. (2000) Soluble granzymes are released during human endotoxemia and in patients with severe infection due to gram-negative bacteria. J Infect Dis 182: 206-213.
24. Choy JC, Hung VH, Hunter AL, Cheung PK, Motyka B, et al. (2004) Granzyme B induces smooth muscle cell apoptosis in the absence of perforin: involvement of extracellular matrix degradation. Arterioscler Thromb Vasc Biol 24: 2245-2250.
25. Higaki Y, Yamada O, Okamura T, Mizoguchi H, Kawashima M, (2001) Granzyme-B-containing lymphocyte involvement in epidermal injury in graft-versus-host disease. Dermatology 202: 94-98.
26. Müllbacher A, Waring P, Tha Hla R, Tran T, Chin S, et al. (1999) Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes. Proceedings of the National Academy of Sciences 96: 13950-13955.
27. Pascoe MD, Marshall SE, Welsh KI, Fulton LM, Hughes DA, (2000) Increased accuracy of renal allograft rejection diagnosis using combined perforin, granzyme B, and Fas ligand fine-needle aspiration immunocytology. Transplantation 69: 2547-2553.
28. Tak PP, Kummer JA, Hack CE, Daha MR, Smeets TJ, et al. (1994) Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum 37: 1735-1743.
29. Kircher B, Schumacher P, Nachbaur D, (2008) Granzymes A and B serum levels in allo-SCT. Bone Marrow Transplant 43: 787-791.
30. Rousalova I, Krepela E, (2010) Granzyme B-induced apoptosis in cancer cells and its regulation (review). Int J Oncol 37: 1361-1378.
31. McIlroy D, Cartron PF, Tuffery P, Dudoit Y, Samri A, et al. (2003) A triple-mutated allele of granzyme B incapable of inducing apoptosis. Proc Natl Acad Sci U S A 100: 2562-2567.
32. Zaitsu M, Yamamoto K, Ishii E, Teramura T, Nakadate N, et al. (2004) High frequency of QPY allele and linkage disequilibrium of granzyme-B in Epstein-Barr-virus-associated hemophagocytic lymphohistiocytosis. Tissue Antigens 64: 611-615.
33. Gaafar A, Aljurf MD, Al-Sulaiman A, Iqniebi A, Manogaran PS, et al. (2009) Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients. Exp Hematol 37: 838-848.
34. Sun J, Bird CH, Thia KY, Matthews AY, Trapani JA, et al. (2004) Granzyme B encoded by the commonly occurring human RAH allele retains pro-apoptotic activity. J Biol Chem 279: 16907-16911.
35. Kawase T, Morishima Y, Matsuo K, Kashiwase K, Inoko H, et al. (2007) High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 110: 2235-2241.
36. Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, et al. (1998) Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 339: 1177-1185.
37. Morishima Y, Yabe T, Matsuo K, Kashiwase K, Inoko H, et al. (2007) Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant 13: 315-328.
38. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, et al. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15: 825-828.
39. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, et al. (1980) Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69: 204-217.
40. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, et al. (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11: 945-956.
41. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, et al. (1997) IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 97: 855-864.
42. Scrucca L, Santucci A, Aversa F, (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40: 381-387.
43. Kanda Y, (2011) EZR on R commander.
44. Gooley TA, Leisenring W, Crowley J, Storer BE, (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18: 695-706.
45. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, et al. (2009) Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 15: 367-369.
46. Sutton VR, Vaux DL, Trapani JA, (1997) Bcl-2 prevents apoptosis induced by perforin and granzyme B, but not that mediated by whole cytotoxic lymphocytes. J Immunol 158: 5783-5790.
47. Classen CF, Ushmorov A, Bird P, Debatin KM, (2004) The granzyme B inhibitor PI-9 is differentially expressed in all main subtypes of pediatric acute lymphoblastic leukemias. Haematologica 89: 1314-1321.
48. Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, et al. (2001) Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A 98: 11515-11520.
49. Bladergroen BA, Meijer CJ, ten Berge RL, Hack CE, Muris JJ, et al. (2002) Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? Blood 99: 232-237.
50. Sutton V, Vaux D, Trapani J, (1997) Bcl-2 prevents apoptosis induced by perforin and granzyme B, but not that mediated by whole cytotoxic lymphocytes. The Journal of Immunology 158: 5783-5790.
51. Metkar SS, Menaa C, Pardo J, Wang B, Wallich R, et al. (2008) Human and mouse granzyme A induce a proinflammatory cytokine response. Immunity 29: 720-733.
52. Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ, (2005) Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 174: 1783-1786.
53. Hernandez-Pigeon H, Jean C, Charruyer A, Haure MJ, Titeux M, et al. (2006) Human keratinocytes acquire cellular cytotoxicity under UV-B irradiation. Implication of granzyme B and perforin. J Biol Chem 281: 13525-13532.